<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36220753</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-9133</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>6 Pt 1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</Title><ISOAbbreviation>J Microbiol Immunol Infect</ISOAbbreviation></Journal><ArticleTitle>Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery.</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>1004</EndPage><MedlinePgn>993-1004</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmii.2022.09.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1684-1182(22)00152-9</ELocationID><Abstract><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">SARS-CoV-2 infection results in a broad spectrum of clinical outcomes, ranging from asymptomatic to severe symptoms and death. Most COVID-19 pathogenesis is associated with hyperinflammatory conditions driven primarily by myeloid cell lineages. The long-term effects of SARS-CoV-2 infection post recovery include various symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a longitudinal study of the innate immune profiles 1 and 3 months after recovery in the Thai cohort by comparing patients with mild, moderate, and severe clinical symptoms using peripheral blood mononuclear cells (n&#xa0;=&#xa0;62).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant increases in the frequencies of monocytes compared to controls and NK cells compared to mild and moderate patients were observed in severe patients 1-3 months post recovery. Increased polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were observed in all recovered patients, even after 3 months. Increased IL-6 and TNF&#x3b1; levels in monocytes were observed 1 month after recovery in response to lipopolysaccharide (LPS) stimulation, while decreased CD86 and HLA-DR levels were observed regardless of stimulation. A multiplex analysis of serum cytokines performed at 1 month revealed that most innate cytokines, except for TNF&#x3b1;, IL4/IL-13 (Th2) and IFN&#x3b3; (Th1), were elevated in recovered patients in a severity-dependent manner. Finally, the myelopoiesis cytokines G-CSF and GM-CSF were higher in all patient groups. Increased monocytes and IL-6- and TNF&#x3b1;-producing cells were significantly associated with long COVID-19 symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results reveal that COVID-19 infection influences the frequencies and functions of innate immune cells for up to 3 months after recovery, which may potentially lead to some of the long COVID symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruenjaiman</LastName><ForeName>Vichaya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sodsai</LastName><ForeName>Pimpayao</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kueanjinda</LastName><ForeName>Patipark</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunrasmee</LastName><ForeName>Worawan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klinchanhom</LastName><ForeName>Siriwan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reantragoon</LastName><ForeName>Rangsima</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tunvirachaisakul</LastName><ForeName>Chavit</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manothummetha</LastName><ForeName>Kasama</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mejun</LastName><ForeName>Nuthchaya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liengswangwong</LastName><ForeName>Kaewkwan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torvorapanit</LastName><ForeName>Pattama</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Thai Red Cross Emerging Infectious Diseases Clinical Centre, King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand; Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paitoonpong</LastName><ForeName>Leilani</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Thai Red Cross Emerging Infectious Diseases Clinical Centre, King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand; Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putcharoen</LastName><ForeName>Opass</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Thai Red Cross Emerging Infectious Diseases Clinical Centre, King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand; Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palaga</LastName><ForeName>Tanapat</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand; Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand. Electronic address: tanapat.p@chula.ac.th.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirankarn</LastName><ForeName>Nattiya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>study team</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Microbiol Immunol Infect</MedlineTA><NlmUniqueID>100956211</NlmUniqueID><ISSNLinking>1684-1182</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Innate immune cells</Keyword><Keyword MajorTopicYN="N">Lipopolysaccharide</Keyword><Keyword MajorTopicYN="N">Post recovery</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Tungwongkitsiri</LastName><ForeName>Abhichaya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mittrakulkij</LastName><ForeName>Chanya</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiewbangyang</LastName><ForeName>Farsai</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaewsrihawong</LastName><ForeName>Janista</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanpakit</LastName><ForeName>Jirayu</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulkiatprasert</LastName><ForeName>Kanokphet</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munkong</LastName><ForeName>Khemmachat</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keawthawon</LastName><ForeName>Nanthida</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wattanakul</LastName><ForeName>Natchanon</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Limchanachon</LastName><ForeName>Natdanai</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roopsuwankun</LastName><ForeName>Natthapat</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaosuwannakij</LastName><ForeName>Natthasini</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larpanekanan</LastName><ForeName>Pasin</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pitakkitnukun</LastName><ForeName>Pawit</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Homswad</LastName><ForeName>Pongpon</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratanapraisorn</LastName><ForeName>Samapitch</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atchariyapakorn</LastName><ForeName>Sarunyapong</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vongphanich</LastName><ForeName>Sasathamon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jessadapornchai</LastName><ForeName>Sirapat</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avihingsanon</LastName><ForeName>Teton</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piyasathapornpong</LastName><ForeName>Thanatorn</ForeName><Initials>T</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>22</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36220753</ArticleId><ArticleId IdType="pmc">PMC9519362</ArticleId><ArticleId IdType="doi">10.1016/j.jmii.2022.09.001</ArticleId><ArticleId IdType="pii">S1684-1182(22)00152-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jordan R.E., Adab P., Cheng K.K. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.</Citation><ArticleIdList><ArticleId IdType="pubmed">32217618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann E.R., Menon M., Knight S.B., Konkel J.E., Jagger C., Shaw T.N., et al. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci Immunol. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857390</ArticleId><ArticleId IdType="pubmed">32943497</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Wimmers F., Mok C.K.P., Perera R., Scott M., Hagan T., et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderbeke L., Van Mol P., Van Herck Y., De Smet F., Humblet-Baron S., Martinod K., et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. 2021;12:4117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8257697</ArticleId><ArticleId IdType="pubmed">34226537</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati C., Sacchi A., Bordoni V., Cimini E., Notari S., Grassi G., et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19) Cell Death Differ. 2020;27:3196&#x2013;3207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278239</ArticleId><ArticleId IdType="pubmed">32514047</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano T., Matsumura T., Adachi Y., Terahara K., Moriyama S., Onodera T., et al. Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan. Int Immunol. 2021;33:241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928855</ArticleId><ArticleId IdType="pubmed">33538817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Presti E., De Gaetano A., Pioggia G., Gangemi S. Comprehensive analysis of the ILCs and unconventional T cells in virus infection: profiling and dynamics associated with COVID-19 disease for a future monitoring system and therapeutic opportunities. Cells. 2022:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8834012</ArticleId><ArticleId IdType="pubmed">35159352</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschler S., Kager J., Erber J., Fricke L., Koyumdzhieva P., Georgieva A., et al. Mucosal-associated invariant T (MAIT) cells are highly activated and functionally impaired in COVID-19 patients. Viruses. 2021:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7913667</ArticleId><ArticleId IdType="pubmed">33546489</ArticleId></ArticleIdList></Reference><Reference><Citation>Flament H., Rouland M., Beaudoin L., Toubal A., Bertrand L., Lebourgeois S., et al. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021;22:322&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">33531712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowitdamrong E., Puthanakit T., Jantarabenjakul W., Prompetchara E., Suchartlikitwong P., Putcharoen O., et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546485</ArticleId><ArticleId IdType="pubmed">33035234</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a M., Kokkinou E., Carrasco Garc&#xed;a A., Parrot T., Palma Medina L.M., Maleki K.T., et al. Innate lymphoid cell composition associates with COVID-19 disease severity. Clin Transl Immunology. 2020;9:e1224&#x2013;e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734472</ArticleId><ArticleId IdType="pubmed">33343897</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman M., Faridi R.M., Sligl W., Shabani-Rad M.-T., Dharmani-Khan P., Parker A., et al. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Advances. 2020;4:5035&#x2013;5039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594380</ArticleId><ArticleId IdType="pubmed">33075136</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi A., Grassi G., Bordoni V., Lorenzini P., Cimini E., Casetti R., et al. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death Dis. 2020;11:921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590570</ArticleId><ArticleId IdType="pubmed">33110074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D., Savale L., Noel N., Meyrignac O., Colle R., Gasnier M., et al. Post-acute COVID-19 syndrome. Eur Respir Rev. 2022:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkstrom N.K., Ponzetta A. Natural killer cells and unconventional T cells in COVID-19. Curr Opin Virol. 2021;49:176&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214213</ArticleId><ArticleId IdType="pubmed">34217135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkstrom N.K., Strunz B., Ljunggren H.G. Natural killer cells in antiviral immunity. Nat Rev Immunol. 2022;22:112&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194386</ArticleId><ArticleId IdType="pubmed">34117484</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi J. NK cell dysfunction in patients with COVID-19. Cell Mol Immunol. 2022;19:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755515</ArticleId><ArticleId IdType="pubmed">35022604</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem G., Cheon S., Lee H., Choi S.J., Jeong S., Kim E.S., et al. Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J Allergy Clin Immunol. 2021;148:996&#x2013;1006 e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324384</ArticleId><ArticleId IdType="pubmed">34339730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A., Salvati L., Maggi L., Capone M., Vanni A., Spinicci M., et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130:4694&#x2013;4703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman M., Faridi R.M., Sligl W., Shabani-Rad M.T., Dharmani-Khan P., Parker A., et al. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv. 2020;4:5035&#x2013;5039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594380</ArticleId><ArticleId IdType="pubmed">33075136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekkering S., Dominguez-Andres J., Joosten L.A.B., Riksen N.P., Netea M.G. Trained immunity: reprogramming innate immunity in health and disease. Annu Rev Immunol. 2021;39:667&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">33637018</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Garg M., Jia T., Liao Q., Yuan L., Li M., et al. Single-cell analysis reveals the immune characteristics of myeloid cells and memory T cells in recovered COVID-19 patients with different severities. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762286</ArticleId><ArticleId IdType="pubmed">35046942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828349</ArticleId><ArticleId IdType="pubmed">19197294</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.J., Nam D.E., Seong H.C., Hahn Y.S. New discovery of myeloid-derived suppressor cell's tale on viral infection and COVID-19. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8850309</ArticleId><ArticleId IdType="pubmed">35185933</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkabets M., Ribeiro V.S., Dinarello C.A., Ostrand-Rosenberg S., Di Santo J.P., Apte R.N., et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40:3347&#x2013;3357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373225</ArticleId><ArticleId IdType="pubmed">21110318</ArticleId></ArticleIdList></Reference><Reference><Citation>Perfilyeva Y.V., Ostapchuk Y.O., Tleulieva R., Kali A., Abdolla N., Krasnoshtanov V.K., et al. Myeloid-derived suppressor cells in COVID-19: a review. Clin Immunol. 2022;238</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9042722</ArticleId><ArticleId IdType="pubmed">35489643</ArticleId></ArticleIdList></Reference><Reference><Citation>Coudereau R., Waeckel L., Cour M., Rimmele T., Pescarmona R., Fabri A., et al. Emergence of immunosuppressive LOX-1+ PMN-MDSC in septic shock and severe COVID-19 patients with acute respiratory distress syndrome. J Leukoc Biol. 2022;111:489&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242532</ArticleId><ArticleId IdType="pubmed">33909917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi A., Grassi G., Bordoni V., Lorenzini P., Cimini E., Casetti R., et al. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death Dis. 2020;11:921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590570</ArticleId><ArticleId IdType="pubmed">33110074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasichaolu, Zhang X., Li X., Li X., Li D. Circulating cytokines and lymphocyte subsets in patients who have recovered from COVID-19. BioMed Res Int. 2020;2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695995</ArticleId><ArticleId IdType="pubmed">33274223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Shen C., Li J., Yuan J., Wei J., Huang F., et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020;146:119&#x2013;127 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189843</ArticleId><ArticleId IdType="pubmed">32360286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang J., Liu C., Su L., Zhang D., Fan J., et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594996</ArticleId><ArticleId IdType="pubmed">33121429</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J., Reusch N., Paclik D., Bassler K., Schlickeiser S., Zhang B., et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182:1419&#x2013;1440 e23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno Fern&#xe1;ndez-Ayala D.J., Navas P., L&#xf3;pez-Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp Gerontol. 2020;142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648491</ArticleId><ArticleId IdType="pubmed">33171276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A., Okorie C., Marinkovic A., Patidar R., Younis K., Desai P., et al. Comorbidity and its impact on patients with COVID-19. SN Comprehensive Clinical Medicine. 2020;2:1069&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C.F., Yen C.L., Fu Y.C., Cheng C.M., Shen T.C., Chang P.D., et al. Innate immune responses of vaccinees determine early neutralizing antibody production after ChAdOx1nCoV-19 vaccination. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822242</ArticleId><ArticleId IdType="pubmed">35145520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschenberger M., Hunszinger V., Sparrer K.M.J. Implications of innate immunity in post-acute sequelae of non-persistent viral infections. Cells. 2021:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391718</ArticleId><ArticleId IdType="pubmed">34440903</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong J.-G., Ravishankar A., Sharma S., Parkhurst C.N., Nehar-Belaid D., Ma S., et al. Epigenetic memory of COVID-19 in innate immune cells and their progenitors. bioRxiv. 2022:2022. 02.09.479588.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>